Sandoz H1 2026 Sales Up 9% to $3.01 Billion, Edging Past Forecasts

Sandoz reported half-year 2026 net sales of $3.01 billion on 5 August, up 9% and narrowly above analyst consensus. Biosimilars — near-copies of biologic drugs — drove the gain. It's the first hard data backing management's February guidance that recently launched biosimilars would accelerate 2026 growth. A Capital Markets Day follows on 8 September in London.